PE20161024A1 - Composiciones solidas de trigliceridos y usos de estas - Google Patents

Composiciones solidas de trigliceridos y usos de estas

Info

Publication number
PE20161024A1
PE20161024A1 PE2016000621A PE2016000621A PE20161024A1 PE 20161024 A1 PE20161024 A1 PE 20161024A1 PE 2016000621 A PE2016000621 A PE 2016000621A PE 2016000621 A PE2016000621 A PE 2016000621A PE 20161024 A1 PE20161024 A1 PE 20161024A1
Authority
PE
Peru
Prior art keywords
triglycerides
solid compositions
compositions
solid
ethylcellulose
Prior art date
Application number
PE2016000621A
Other languages
English (en)
Spanish (es)
Inventor
Steven Jungles
Gabrielle Morris
John Klopp
Emil Kakkis
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53058066&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161024(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of PE20161024A1 publication Critical patent/PE20161024A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1664—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
PE2016000621A 2013-11-14 2014-11-14 Composiciones solidas de trigliceridos y usos de estas PE20161024A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361904369P 2013-11-14 2013-11-14

Publications (1)

Publication Number Publication Date
PE20161024A1 true PE20161024A1 (es) 2016-11-10

Family

ID=53058066

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2016000621A PE20161024A1 (es) 2013-11-14 2014-11-14 Composiciones solidas de trigliceridos y usos de estas

Country Status (18)

Country Link
US (6) US20160243071A1 (https=)
EP (2) EP3782610A1 (https=)
JP (4) JP2017501972A (https=)
KR (1) KR102291310B1 (https=)
CN (2) CN113181158A (https=)
AR (2) AR099353A1 (https=)
AU (1) AU2014348470B2 (https=)
CA (2) CA2929688C (https=)
CL (1) CL2016001130A1 (https=)
ES (1) ES2833294T3 (https=)
IL (1) IL245588B (https=)
MX (2) MX383005B (https=)
MY (1) MY177028A (https=)
PE (1) PE20161024A1 (https=)
PH (1) PH12016500821A1 (https=)
RU (1) RU2016123169A (https=)
TW (1) TWI640327B (https=)
WO (1) WO2015073816A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI640327B (zh) 2013-11-14 2018-11-11 美商奧崔基尼克斯製藥公司 三酸甘油酯之固體組合物及其用途
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US12419852B2 (en) 2018-08-27 2025-09-23 Exerkine Corporation Method for treating lysosomal storage disease
US11583542B2 (en) 2019-12-16 2023-02-21 Amylyx Pharmaceuticals, Inc. Compositions of bile acids and phenylbutyrate compounds
CN113476408A (zh) * 2021-07-23 2021-10-08 兆科药业（广州）有限公司 一种苯丁酸甘油酯颗粒剂及其制备方法与应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3337596A (en) 1965-02-18 1967-08-22 Procter & Gamble Synthesis of mixed glycerides
JPS5215834A (en) 1975-07-12 1977-02-05 Ajinomoto Kk Method of producing food composition
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JPH07102106B2 (ja) 1987-06-10 1995-11-08 日清製粉株式会社 経口，経管栄養食の製造法
KR100318295B1 (ko) 1989-07-05 2002-11-16 가부시키가이샤 저펜에너지 냉각윤활제
EP0421581A1 (en) 1989-10-03 1991-04-10 Warner-Lambert Company Chewable spray dried spheroidal microcapsules and wax coated microcapsules and methods for preparing same
JPH0692848A (ja) 1992-09-11 1994-04-05 Sagami Chem Res Center 糖尿病治療用乳剤
JPH06145688A (ja) 1992-11-10 1994-05-27 Nippon San Sekiyu Kk 冷凍機用潤滑油組成物
JP2800610B2 (ja) * 1992-12-15 1998-09-21 不二製油株式会社 水中油型乳化物の製造法
JP3522843B2 (ja) * 1994-07-29 2004-04-26 昭和産業株式会社 リポ製剤
US5746933A (en) 1994-11-07 1998-05-05 Nippon Oil Co., Ltd. Lubricating oil and composition for refrigerating machine, and refrigerating machine
ES2157422T3 (es) 1995-02-07 2001-08-16 Brusilow Entpr Llc Trigliceridos y esteres etilicos de acido fenilalcanoico y acido fenilalquenoico utiles en el tratamiento de diversos trastornos.
US5698210A (en) 1995-03-17 1997-12-16 Lee County Mosquito Control District Controlled delivery compositions and processes for treating organisms in a column of water or on land
JPH08311480A (ja) * 1995-05-18 1996-11-26 D H Ee Kodo Seisei Chushutsu Gijutsu Kenkyu Kumiai 高純度トリアシルグリセロールからなる油脂の製造方法及び高度不飽和脂肪酸含有油脂組成物
EP0903335B1 (en) 1995-09-25 2002-11-27 Kao Corporation Use of ester compounds in lubricating oil compositions
US5908631A (en) * 1997-02-27 1999-06-01 L'oreal S.A. Monohydric alcohol-free composition for topical use comprising solubilized ethylcellulose
US5885616A (en) 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6278006B1 (en) 1999-01-19 2001-08-21 Cargill, Incorporated Transesterified oils
EP1150579B1 (en) 1999-02-05 2005-08-31 Baylor Research Institute Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven carbon fatty acid
US20030162833A1 (en) 2001-08-01 2003-08-28 Roe Charles R. Fatty acid treatment for cardiac patients
DE60130083T2 (de) 2000-10-16 2008-05-15 Nof Corp. Herstellung von Estern für die Verwendung als Basisschmieröl
JP4282289B2 (ja) 2002-08-29 2009-06-17 株式会社ジャパンエナジー 流体軸受用潤滑油及びそれを用いた流体軸受
JPWO2004022050A1 (ja) 2002-09-05 2005-12-22 日清オイリオグループ株式会社 脂質代謝調整剤および飲食物
US8399515B2 (en) * 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
US20050058673A1 (en) 2003-09-09 2005-03-17 3M Innovative Properties Company Antimicrobial compositions and methods
WO2005120484A1 (ja) 2004-06-09 2005-12-22 Kurume University グレリンの生理学的機能のレギュレーター
US7141114B2 (en) * 2004-06-30 2006-11-28 Rec Silicon Inc Process for producing a crystalline silicon ingot
US8106093B2 (en) 2004-07-02 2012-01-31 Baylor Research Institute Glycogen or polysaccharide storage disease treatment method
KR20070113281A (ko) * 2005-03-10 2007-11-28 쓰리엠 이노베이티브 프로퍼티즈 컴파니 항미생물성 조성물 및 방법
EP1858506A2 (en) * 2005-03-10 2007-11-28 3M Innovative Properties Company Methods of treating ear infections
FR2894822B1 (fr) 2005-12-20 2011-11-18 Pf Medicament Composition pharmaceutique contenant des acides gras omega-3
US20090017118A1 (en) 2006-02-10 2009-01-15 Sportscom Danmark Aps Coated tablets, their methods of preparation, and related uses
JP5099808B2 (ja) 2006-05-29 2012-12-19 独立行政法人農業・食品産業技術総合研究機構 脂質代謝改善用組成物
JP2010526123A (ja) 2007-05-08 2010-07-29 ディーエスエム アイピー アセッツ ビー．ブイ． 体重維持および体組成
JP5296366B2 (ja) * 2007-10-29 2013-09-25 日清オイリオグループ株式会社 医薬品用持久力向上剤および持久力向上用医薬品
CN102046202A (zh) 2008-03-26 2011-05-04 塔罗制药北美有限公司 用于口服药剂的稳定脂质组合物
PL3133396T3 (pl) 2008-04-29 2019-03-29 Horizon Therapeutics, Llc Sposób leczenia z zastosowaniem leków wychwytujących amoniak
PT3133396T (pt) 2008-08-29 2018-12-07 Immedica Pharma Ab Métodos de tratamento utilizando fármacos eliminadores de amoníaco
CA2785714C (en) 2009-12-30 2016-01-26 Baylor Research Institute Anaplerotic therapy for alzheimer's disease and the aging brain
CN103079555A (zh) * 2010-06-14 2013-05-01 贝勒研究院 用于成人葡萄糖多聚体病（apbd）治疗的三庚酸甘油酯膳食
US8932646B2 (en) 2010-06-18 2015-01-13 Bausch & Lomb Incorporated Peroxide contact lens care solution
CN101919453B (zh) * 2010-08-16 2013-04-10 苏州市佳禾食品工业有限公司 中碳链脂肪酸粉末油脂及其制备方法
JP5820256B2 (ja) 2011-02-10 2015-11-24 株式会社ファンケル 自己乳化製剤
WO2013012699A2 (en) 2011-07-15 2013-01-24 3M Innovative Properties Company Polyurethane based coating compositions
DK2760479T3 (en) 2011-09-30 2017-07-17 Horizon Therapeutics Llc Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder
WO2013121906A1 (ja) 2012-02-15 2013-08-22 日清オイリオグループ株式会社 飼料用組成物、飼料、及び飼料の製造方法
TWI572352B (zh) 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 用於製備具中鏈長度之脂肪酸的三酸甘油酯之方法
EP2838522B1 (en) * 2012-04-16 2024-02-21 University of Pittsburgh - Of the Commonwealth System of Higher Education Phenylbutyrate for the treatment of medium-chain acyl-coa dehydrogenase deficiency
ES2728727T3 (es) 2012-12-13 2019-10-28 Baylor Res Institute At Dallas Triheptanoína para el tratamiento de la deficiencia del transportador de glucosa 1
EP3027180B1 (en) 2013-07-31 2021-07-07 The Children's Hospital of Philadelphia Compositions and methods of the treatment of fatty acid metabolism disorders
TWI640327B (zh) 2013-11-14 2018-11-11 美商奧崔基尼克斯製藥公司 三酸甘油酯之固體組合物及其用途
US11844775B2 (en) 2018-07-11 2023-12-19 University of Pittsburgh—of the Commonwealth System of Higher Education Method of treating fatty acid oxidation disorders using Omega3/Omega6 unsaturated or branched chain fatty acids

Also Published As

Publication number Publication date
JP2020111585A (ja) 2020-07-27
AR099353A1 (es) 2016-07-20
US20200069631A1 (en) 2020-03-05
JP2022107017A (ja) 2022-07-20
MX2016006329A (es) 2016-09-06
JP2024129109A (ja) 2024-09-26
CN105764497A (zh) 2016-07-13
PH12016500821A1 (en) 2016-06-13
IL245588B (en) 2021-08-31
KR102291310B1 (ko) 2021-08-23
US20230181513A1 (en) 2023-06-15
EP3068383A1 (en) 2016-09-21
CL2016001130A1 (es) 2017-01-20
AR130666A2 (es) 2025-01-08
ES2833294T3 (es) 2021-06-14
EP3068383A4 (en) 2017-11-08
EP3068383B1 (en) 2020-09-16
US20160243071A1 (en) 2016-08-25
WO2015073816A1 (en) 2015-05-21
AU2014348470A1 (en) 2016-05-26
US20250120936A1 (en) 2025-04-17
TW201609189A (zh) 2016-03-16
CN113181158A (zh) 2021-07-30
TWI640327B (zh) 2018-11-11
CA2929688A1 (en) 2015-05-21
MX2021001790A (es) 2021-04-19
RU2016123169A (ru) 2017-12-19
CA3197154A1 (en) 2015-05-21
US20250120934A1 (en) 2025-04-17
CA2929688C (en) 2023-06-13
US20250120935A1 (en) 2025-04-17
AU2014348470B2 (en) 2020-01-30
MY177028A (en) 2020-09-02
IL245588A0 (en) 2016-06-30
US12551461B2 (en) 2026-02-17
JP2017501972A (ja) 2017-01-19
MX383005B (es) 2025-03-13
KR20160084407A (ko) 2016-07-13
EP3782610A1 (en) 2021-02-24

Similar Documents

Publication Publication Date Title
UA114615C2 (uk) Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
SG11201600337PA (en) SELF-EMULSIFYING COMPOSITION OF ω-3 FATTY ACID
IL234814A (en) Omega 3 fatty acid ester preparations
EA201590026A1 (ru) Выработка длинноцепочечных полиненасыщенных жирных кислот в растительных клетках
PE20191815A1 (es) Formulaciones acuosas estables de adalimumab
EP3735963C0 (en) SELF-EMULSIFYING COMPOSITION OF OMEGA-3 FATTY ACIDS
PE20161024A1 (es) Composiciones solidas de trigliceridos y usos de estas
EP3065885A4 (en) Aqueous polyelectrolyte complex as one pot nanocoating solution to impart antiflammable behavior to various substrates
IN2015DN03281A (https=)
EP3232770A4 (en) Generation of transgenic canola with low or no saturated fatty acids
AR087254A1 (es) Gliceratos de metales alcalinos y alcalinoterreos para la desacidificacion y secado de esteres de acidos grasos
MX357165B (es) Composiciones de plastificante y metodos para fabricar composiciones de plastificante.
MX370990B (es) Ésteres de ácidos oligo-hidroxicarboxílicos y uso de los mismos.
SG11201508558QA (en) Immobilized catalytically active composition for hydroformylation of olefin-containing mixtures
MX2015016490A (es) Esteres sulfatados de acidos oligohidroxicarboxilicos, y uso de los mismos.
MY171741A (en) Process for manufacturing biofuels
PL3073843T3 (pl) Kompozycja zmniejszająca szkodliwe działania alkoholu
AR090554A1 (es) Compuestos de acido bencen-policarboxilico
IN2013CH05282A (https=)
EP3041944A4 (en) Conversion of glycerol to 1,3-propanediol under haloalkaline conditions
MX348893B (es) Composicion blanqueadora.
HK1229640A1 (en) Composition to alleviate detrimental effects of alcohol

Legal Events

Date Code Title Description
FA Abandonment or withdrawal